Finasteride and Ketoconazole Interaction: Synergistic | Peptide Database

Join others researching Tamoxifen — share findings, ask questions, and learn from real experiences Tamoxifen is a first-generation selective estrogen receptor modulator (SERM) that has been in clinical use since the 1970s. It is FDA-approved for the treatment and prevention of estrogen receptor-positive breast cancer and remains one of the most widely prescribed cancer therapies worldwide. In the context of performance enhancement, tamoxifen is used extensively for post-cycle therapy (PCT) to restore the hypothalamic-pituitary-testicular axis after suppression from anabolic steroids, and for on-cycle gynecomastia prevention by blocking estrogen receptors in breast tissue. Tamoxifen acts as an estrogen antagonist in breast and hypothalamic tissue while functioning as a partial estrogen agonist in bone, the uterus, and the cardiovascular system. Its active metabolite endoxifen, produced via CYP2D6 metabolism, is responsible for much of its pharmacological activity. Tamoxifen competitively binds to estrogen receptors (primarily ERalpha) and exerts tissue-selective effects depending on the local coactivator and corepressor environment. In breast tissue and the hypothalamus, tamoxifen acts as an estrogen antagonist, blocking estradiol-mediated signaling. At the hypothalamus and anterior pituitary, this antagonism removes estrogen-driven negative feedback on GnRH secretion, leading to increased pulsatile GnRH release and subsequent elevation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The rise in LH stimulates Leydig cell testosterone production, which is the basis for its use in post-cycle therapy. In bone tissue, tamoxifen acts as a partial estrogen agonist, providing a protective effect on bone mineral density. Tamoxifen is a prodrug that requires hepatic metabolism via CYP3A4 and CYP2D6 to generate its active metabolites, particularly endoxifen, which has approximately 100-fold greater affinity for the estrogen receptor than the parent compound.

First-line pharmacotherapy for ED of various etiologies including psychogenic, vasculogenic, and mixed. Effective in a broad range of patient populations including those with diabetes and post-prostatectomy. Daily low-dose tadalafil maintains steady plasma levels, allowing for spontaneous sexual activity without the need to time dosing around intercourse. FDA-approved at 5mg daily for treatment of BPH signs and symptoms, including urinary frequency, urgency, weak stream, and nocturia. Can be used alone or with alpha-blockers. Relaxes smooth muscle in the prostate, bladder neck, and urethra via PDE5 inhibition, improving urinary flow and reducing symptom severity. FDA-approved as Adcirca (40mg daily) for PAH (WHO Group 1) to improve exercise ability. Relaxes pulmonary vasculature and reduces right ventricular afterload. Enhances NO-cGMP signaling in systemic vasculature, improving flow-mediated dilation and arterial compliance. May slow progression of endothelial dysfunction. Modest systemic vasodilation produces small but clinically meaningful reductions in systolic and diastolic blood pressure, particularly in patients with mild hypertension. Enhanced NO-mediated vasodilation may increase blood flow to working muscles during resistance training, producing a more pronounced pump effect. Evidence is largely anecdotal but mechanistically plausible. Some evidence suggests PDE5 inhibition can improve exercise performance at altitude by reducing pulmonary artery pressure and improving oxygen delivery.